Drug Interactions between nefazodone and pravastatin
This report displays the potential drug interactions for the following 2 drugs:
- nefazodone
- pravastatin
Interactions between your drugs
pravastatin nefazodone
Applies to: pravastatin and nefazodone
MONITOR: An isolated case report suggests a possible interaction between nefazodone and pravastatin resulting in presumed musculoskeletal toxicity manifested as asymptomatic elevations in creatine kinase level. The mechanism of interaction is unknown, as nefazodone has not been shown to significantly affect pravastatin metabolism or plasma levels. The patient was a 74-year-old man treated with aspirin, atenolol, citalopram, and pravastatin. Citalopram was replaced with nefazodone 50 mg twice daily, and 36 hours later, the patient's creatine kinase level was 877 U/L (baseline level not reported). Lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase were slightly elevated (less than 3 times the upper limit of normal). Following withdrawal of nefazodone, creatine kinase levels declined but remained elevated, so pravastatin was also withdrawn 14 days later. The patient subsequently tolerated pravastatin with venlafaxine 75 mg twice daily without problems.
MANAGEMENT: All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.
References (4)
- (2001) "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb
- Alderman CP (1999) "Possible interaction between nefazodone and pravastatin." Ann Pharmacother, 33, p. 871
- Bottorf MB (2000) "Possible interaction between nefazodone and pravastatin." Ann Pharmacother, 34, p. 538
- Alderman CP (2000) "Possible interaction between nefazodone and pravastatin." Ann Pharmacother, 34, p. 538-9
Drug and food interactions
nefazodone food
Applies to: nefazodone
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
pravastatin food
Applies to: pravastatin
MONITOR: Concomitant use of statin medication with substantial quantities of alcohol may increase the risk of hepatic injury. Transient increases in serum transaminases have been reported with statin use and while these increases generally resolve or improve with continued therapy or a brief interruption in therapy, there have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Active liver disease or unexplained transaminase elevations are contraindications to statin use.
MANAGEMENT: Patients should be counseled to avoid substantial quantities of alcohol in combination with statin medications and clinicians should be aware of the increased risk for hepatotoxicity in these patients.
References (9)
- (2001) "Product Information. Pravachol (pravastatin)." Bristol-Myers Squibb
- (2001) "Product Information. Zocor (simvastatin)." Merck & Co., Inc
- (2001) "Product Information. Lescol (fluvastatin)." Novartis Pharmaceuticals
- (2001) "Product Information. Lipitor (atorvastatin)." Parke-Davis
- (2002) "Product Information. Altocor (lovastatin)." Andrx Pharmaceuticals
- (2003) "Product Information. Crestor (rosuvastatin)." AstraZeneca Pharma Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2010) "Product Information. Livalo (pitavastatin)." Kowa Pharmaceuticals America (formerly ProEthic)
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.